Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 3
2008 7
2009 2
2010 3
2011 5
2012 3
2013 5
2014 7
2015 8
2016 2
2017 8
2018 4
2019 10
2020 10
2021 16
2022 19
2023 21
2024 26
2025 20
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean kiyoshi nakahara (25 results)?
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.
Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Fujimoto S, Minami T, Yamamoto Y, Yamazaki S, Takai T, Sakamoto M, Nakajima Y, Nishimura K, Maenosono R, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yoshikawa Y, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Fujita K, Kimura T, Ohno Y, Shiroki R, Azuma H. Uchimoto T, et al. Among authors: takahara k. Int J Clin Oncol. 2025 Jan;30(1):123-133. doi: 10.1007/s10147-024-02649-2. Epub 2024 Oct 28. Int J Clin Oncol. 2025. PMID: 39467994
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, Hayashi T, Ura A, Ohno T, Yamazaki S, Nakamori K, Kinoshita S, Maenosono R, Ajiro M, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Konuma T, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Among authors: takahara k. Mol Cancer. 2023 Nov 18;22(1):185. doi: 10.1186/s12943-023-01897-6. Mol Cancer. 2023. PMID: 37980528 Free PMC article.
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study.
Nukaya T, Takahara K, Toyoda S, Inoki L, Fukuokaya W, Mori K, Iwata T, Bekku K, Maenosono R, Tsujino T, Hirasawa Y, Yanagisawa T, Hashimoto T, Komura K, Araki M, Fujita K, Ohno Y, Shiroki R. Nukaya T, et al. Among authors: takahara k. Int J Urol. 2025 Nov;32(11):1677-1685. doi: 10.1111/iju.70207. Epub 2025 Aug 19. Int J Urol. 2025. PMID: 40831087 Free PMC article.
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.
Nishio K, Hirosuna K, Uchimoto T, Niigawa H, Kakumae S, Jo T, Morinaka H, Fukuokaya W, Yoshizawa A, Saruta M, Hashimoto M, Minami T, Yamamoto Y, Sakamoto M, Nishimura K, Maenosono R, Tsujino T, Yoshikawa Y, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Fujita K, Kimura T, Azuma H, Komura K. Nishio K, et al. Among authors: takahara k. Anticancer Res. 2025 Oct;45(10):4575-4583. doi: 10.21873/anticanres.17803. Anticancer Res. 2025. PMID: 41006037
Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy.
Sugimoto K, Minami T, Toyoda S, Inoki L, Nukaya T, Takahara K, Adachi T, Hashimoto T, Maenosono R, Tsujino T, Fukuokaya W, Yanagisawa T, Iwata T, Bekku K, Araki M, Kimura T, Azuma H, Ohno Y, Shiroki R, Fujita K; JK-FOOT STUDY GROUP. Sugimoto K, et al. Among authors: takahara k. Anticancer Res. 2025 Aug;45(8):3355-3364. doi: 10.21873/anticanres.17696. Anticancer Res. 2025. PMID: 40750399
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium.
Yanagisawa T, Mori K, Kawada T, Katayama S, Tsujino T, Maenosono R, Toyoda S, Nukaya T, Morinaka H, Tamura K, Fukuokaya W, Urabe F, Murakami M, Bekku K, Takahara K, Fujita K, Azuma H, Araki M, Inamoto T, Komura K, Kimura T; JK-FOOT study group. Yanagisawa T, et al. Among authors: takahara k. Cancer Immunol Immunother. 2026 Feb 25;75(3):84. doi: 10.1007/s00262-025-04288-6. Cancer Immunol Immunother. 2026. PMID: 41739193 Free PMC article.
169 results